Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Lonza has licensed CRISPR-Cas9 gene-editing technology from ERS Genomics for use in its new cell biology research division. The drug services firm is adding gene editing to improve the development of cell lines, according to Sarah Holland, head of licensing for Lonza’s biologics business. “If you are going to create and improve cell lines, you really need effective modern tools, and one of those is CRISPR-Cas9,” Holland says. The new research section plans to license another gene-editing technology in 2019, she says.
This article has been sent to the following recipient: